Pacific Northwest Society of Pathologists



From this document you will learn the answers to the following questions:

What type of pathology did the speaker discuss?

Who was the speaker at the 2009 meeting?

Who was the speaker at the 2009 Pacific Northwest Society of Pathologists meeting?

Similar documents
Case of the. Month October, 2012

Advances in Lung Cancer: A Multidisciplinary Approach

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Recruiting now. Could you help by joining this study?

If you are signing for a minor child, you refers to your child throughout the consent document.

Lung Cancer: More than meets the eye

3rd Annual Jefferson Lung Cancer Symposium

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Ovarian tumors Ancillary methods

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

Lung Cancer & Mesothelioma

Plaintiffs Experts Latest Pathological Theories

International Journal of Case Reports in Medicine

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

Diagnosis of Mesothelioma Pitfalls and Practical Information

Developments in Biomarker Identification and Validation for Lung Cancer

The following information is only meant for people who have been diagnosed with advanced non-small cell

Diagnostic Challenge. Department of Pathology,

Targeted Therapies in Lung Cancer

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

YOUR LUNG CANCER PATHOLOGY REPORT

LUNG CANCER. FCDS 2011 Educational Webcast Series November 17, 2011

Adekunle M Adesina, M.D., Ph.D

Practical Effusion Cytology

Small Cell Lung Cancer

2011 Pulmonary Pathology Society Biennial Meeting Program

QUESTIONS FOR YOUR LUNG CANCER CARE TEAM

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Targeted Therapy What the Surgeon Needs to Know

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

Pathology of lung cancer

What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide

General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

A 70-year old Man with Pleural Effusion

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Uses and Abuses of Pathology in Asbestos-exposed Populations

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

May 18, 2013 Sheraton Delfina Santa Monica, California

Lung Cancer Treatment Guidelines

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

PET/CT in Lung Cancer

Something Old, Something New.

Lung Cancer. This reference summary will help you better understand lung cancer and the treatment options that are available.

HER2 Testing in Breast Cancer

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

SPECT and PET imaging in porcine inflammation and infection models. UCPH pig model network seminar

Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

PRIMARY LUNG CANCER TREATMENT

Summary ID# Clinical Study Summary: Study H3E-EW-B012

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA

Update on Mesothelioma

HOW TO FILE ACCIDENT AFLAC CLAIM

Hepatocellular Carcinoma: What the hepatologist wants to know

Oncology Programme. Oncology Programme August 2015 Page 1 of 15

What You Need to Know About Lung Cancer Immunotherapy

FASEB Directory of Members Online


Adler v 3M Co NY Slip Op 32796(U) October 28, 2013 Sup Ct, New York County Docket Number: /2012 Judge: Sherry Klein Heitler Cases posted

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Activity of pemetrexed in thoracic malignancies

why? 75 percent The percentage of healthy individuals over age 40 who will become critically ill at some time in the future. 3

targeted therapy a guide for the patient

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? Telephone

An Update on Lung Cancer Diagnosis

Cytopathology Case Presentation #8

Us TOO University Presents: Understanding Diagnostic Testing

Primary -Benign - Malignant Secondary

Secondary Uses of Data for Comparative Effectiveness Research

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Endpoint Selection in Phase II Oncology trials

General Information About Non-Small Cell Lung Cancer

PATHOLOGY DEPARTMENTS AT GRADUATE MEDICAL EDUCATION TEACHING INSTITUTIONS

CURRICULUM VITAE. Hana A. Razek, M.D.

May 21, 2011 Sheraton Delfina Santa Monica, California

Houston Cancer Institute

Moving Beyond RECIST

Transcription:

Pacific Northwest Society of Pathologists Activity Title: 2009 Spring Meeting Location: Fred Hutchinson Cancer Research Center, Seattle, WA Objectives for this Session Understand the history of medical error disclosure and recent legal developments Identify the error disclosure issues unique to pathology Recognize the relevance of sub-histology of non-small cell lung cancer (NSCLC) in selection of optimal chemotherapy choice for advance NSCLC Understand the potential utility of molecular markers such as ERCC-1, RRM-1, and others in selecting chemotherapy choices for patients with advanced NSCLC Assess the potential value of molecular markers of the epidermal growth factor receptor axis in individualizing treatment recommendations for patients with NSCLC. Identify the pathological features of mesothelioma Identify the use of specialized testing in diagnosing mesothelioma Identify the new approach to neuroendocrine epithelial lung tumors Describe the features of lung allograft rejection Analyze their own lab to identify places where errors occur Define how barcoding technologies can eliminate labeling errors Demonstrate recently described patterns of lung cancer pathology Provide a conceptual framework for understanding bronchiolar pathology and show the correlation between bronchiolar pathology and CT scanning Provide basic knowledge of lung CT for Pathologists and show how CT findings can help in pathologic interpretation Recognize certain lesions of bone that may mimic a sarcoma and recognize histopathological and radiological features that are necessary in distinguishing a pseudosarcomatous tumor from sarcoma Speakers: Thomas Colby, MD, Jack West, MD, Ben Hoch, MD, Mark Wick, MD, Samuel Hammar, MD, Susanne Dintzis, MD, PhD, Rodney Schmidt, MD. Disclosure statements: Yes Overall Program Evaluation: Objectives Objectives Objectives Not Met Met Overall course content Excellent Unsatisfactory Overall program organization Organized Unorganized Your perception of enhanced professional effectiveness Will Enhance Effectiveness Will Not Enhance Effectiveness Materials Organized Unorganized Materials Relevant Not Relevant

Mark Wick Benign/Borderline Lung Tumors Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Thomas Colby Lung Cancer Update Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Suzanne Dintzis Disclosing Harmful Pathology Errors to Patients Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Samuel Hammar The Macroscopic, Histologic, Histochemical, Immunohistochemical and Ultrastructural feature of Mesothelioma Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Mark Wick Neuroendocrine Lung Tumors Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent

Thomas Colby Bronchiolitis Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Rodney Schmidt Error Reduction Opportunities in the AP Lab Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Thomas Colby Pathologic-Radiologic correlation in Diffuse Lung Disease Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Jack West Individualized Treatment Decisions Based on Pathology Variables in Lung Cancer Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent Ben Hoch Diagnostic Challenges in Bone Pathology: Reactive Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent

Mark Wick Lung Transplant Reject Content Informative Uninformative Presentation Interesting Boring Speaker knowledge of content Competent Incompetent 1.Please tell us about yourself: A. [ ] MD/DO Specialty: [ ] Administrator/Manager [ ] Other B. Type of organization: [ ] Private practice [ ] Group Practice (# in group ) [ ] IPA/PHO [ ] Hospital Medical Staff [ ] County Medical Society [ ] State Specialty Society [ ] Other 2. To what extent did this course meet your expectation? (Circle one) Exceeded On Target Okay So/So Low 3. Do you feel that the presentation was fair, balanced, and free of commercial bias? If no, please explain. 4. As a result of attending this activity, how will you change your practice? 5. Comments and suggestions: 6. Future topic and speaker suggestions:

For CME Credit: Please complete the following only if you are claiming hours less than the maximum. I attended this course: Date: for hours of CME credit. Name (please print) Signature: